Summit Therapeutics Inc. has announced plans to initiate its global Phase III HARMONi-10 trial, evaluating ivonescimab against durvalumab as consolidation therapy. The study will enroll patients with locally advanced, unresectable Stage III non-small cell lung cancer whose disease has not progressed following platinum-based concurrent chemoradiation therapy. Global clinical trial site activations are expected to begin in the fourth quarter of 2026.
HARMONi-10 is Summit’s sixth sponsor-led Phase III study of ivonescimab and its fourth in non-small cell lung cancer, following HARMONi, HARMONi-3, and HARMONi-7. The trial extends the company’s global clinical development program into the locally advanced, unresectable setting, where durvalumab after curative-intent chemoradiation represents the current standard of care.
Ivonescimab, known as SMT112 within Summit’s license territories, is an investigational bispecific antibody that combines PD-1 blockade with VEGF inhibition in a single molecule, integrating immunotherapy with anti-angiogenic activity. The therapy has not been approved by any regulatory authority in Summit’s license territories, including the United States and Europe.
Also Read
- Take-Two Shares Climb Over 6% as ‘Grand Theft Auto VI’ Debuts After 13-Year Development
- Xi Welcomes Trump and Putin in Shenzhen Ahead of Landmark APEC Trilateral Summit
- MetaVia Faces Nasdaq Deficiency Notice Over Falling Stockholders’ Equity
- Saudi-Led Coalition Intercepts Houthi Missile Bound for Riyadh as Falling Debris Causes Damage


